Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOMAB-ACT in R/R DLBCL
NCT06768905Phase 2Recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of apamistamab in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoints: Dose-limiting toxicity and Complete response at Day 100. Started Apr 2025; status: recruiting.
02
Drugs
apamistamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06768905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768905.